Introduction {#Sec1}
============

Several epidemiological studies show a positive association between plasma thyroid hormones (TH)---triiodothyronine (T~3~) and the prohormone thyroxine (T~4~)---levels and breast cancer risk \[[@CR1]--[@CR3]\], which supports the notion that TH promote tumor growth \[[@CR4]\]. Indeed, in patients with hypothyroidism, breast cancer tends to be diagnosed at an older age and in a less advanced stage, suggesting that hypothyroidism protects against breast cancer and is associated with more indolent disease \[[@CR5]\]. Hypothyroidism may protect against breast cancer, because TH directly stimulate tumor growth via T~3~ receptors (TR) \[[@CR5]\], or because hypothyroidism is associated with reduced serum concentrations of insulin-like growth factor 1 \[[@CR4], [@CR6], [@CR7]\]. Moreover, TH have estrogen-like effects \[[@CR8], [@CR9]\], whereby T~3~ may have the ability to mimic or enhance the effects of estradiol on breast cancer proliferation by binding to the estrogen receptor \[[@CR9], [@CR10]\]. In rodent tumor models, TH stimulate tumor growth, metastasis, and angiogenesis via integrin αvβ3, possibly mediated by phosphatidylinositol-3-kinase and MAPK \[[@CR11], [@CR12]\]. Clinical studies show that treatment-induced hypothyroidism, either by concomitant propylthiouracil or by cancer treatment itself, is associated with a favorable outcome in several cancer types \[[@CR6], [@CR13]\]. In a case control study, euthyroid patients with breast cancer had significantly higher TH levels than their healthy controls \[[@CR14]\]. Thus, although only a few cases of overt hypothyroidism (probably induced by locoregional radiotherapy) after breast cancer therapy were reported \[[@CR15]--[@CR17]\], even a slight decrease of THs in breast cancer patients treated with chemotherapy \[[@CR18]\] could be of clinical relevance.

The influence of TH on effectiveness of chemotherapy remains unclear to date \[[@CR19]\]. We aimed to elucidate the effect of chemotherapy on thyroid function and the predictive value of thyroid function on pathological complete response (pCR) in early breast cancer patients receiving neoadjuvant chemotherapy.

Patients and methods {#Sec2}
====================

Patients {#Sec3}
--------

Women eligible for the NEOZOTAC study had a histologically confirmed HER2-negative stage II or III breast cancer, and further in- and exclusion criteria have been described previous \[[@CR20]\]. A subgroup participated in a side study measuring plasma fT4 and TSH concentrations before cycle 1, 2, and 6 of chemotherapy. Eleven of the participating centers of the NEOZOTAC participated in the side study; patients gave informed consent for extra blood sampling.

Study design {#Sec4}
------------

The NEOZOTAC study was an open label randomized phase III study, running in 26 hospitals in the Netherlands, which compared the efficacy of neoadjuvant chemotherapy with or without zoledronic acid. Eleven of the 26 hospitals participated in the side study. The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committees of the participating hospitals in agreement with the Dutch law for medical research involving humans.

Drugs {#Sec5}
-----

Women received TAC (75 mg/m^2^ of docetaxel i.v. in 1 h, 50 mg/m^2^ of doxorubicin i.v. in 15 min and 500 mg/m^2^ of cyclophosphamide i.v. in 1 h) on the first day of each of six 21-day cycles with or without 4 mg zoledronic acid i.v. in 15 min within 24 h after infusion of chemotherapy. Patients received premedication with dexamethasone (8 mg, b.i.d. the day before, the day of and the day after chemotherapy administration) in order to prevent fluid retention and hypersensitivity reactions. Granulocyte-colony stimulating factor (pegfilgrastim 6 mg) support was given the day after chemotherapy administration.

Blood sampling and analysis {#Sec6}
---------------------------

Non-fasting blood samples were obtained directly before chemotherapy administration (baseline), before the second and before the sixth chemotherapy cycle (end of therapy) to measure fT4 and TSH levels. Samples were collected in EDTA tubes and directly kept on ice after drawing. After centrifuging, the supernatant was stored at −80 °C, and at the end of the study sent to the Leiden University Medical Center (LUMC) for analysis.

TSH and fT4 were determined by Modular Analytics E170 (Roche Diagnostics, Almere, The Netherlands) with chemiluminescence methods by the clinical laboratory of the LUMC. The following reference ranges were used; TSH 0.3--4.8 mU/L and fT4 is 12--22 pmol/L.

Response and toxicity evaluation {#Sec7}
--------------------------------

Central review of operation specimens was performed according to Dutch guidelines. Tumor regression was scored according to the Miller and Payne classification \[[@CR21]\]. Pathological complete response (pCR) was defined as the absence of residual invasive cancer within the breast and lymph nodes.

All adverse events, grade II or more (according to NCI-CTCv4.0) reported spontaneously by the patient or observed by the treating physician or investigator, were recorded on an adverse event case report form. The relationship to the study drug(s) was recorded.

Statistical analysis {#Sec8}
--------------------

We performed an intention-to-treat analysis. All parameters were tested for normality using the Kolmogorov--Smirnov test, with Bonferroni adjustment when evaluated in subgroups. The normally distributed parameters were summarized as 'mean ± standard error (SE)' and compared using t-tests for paired groups. All *t*-tests and regression models were 2-sided with a significance level of 0.05. Univariate and multivariate odds ratios (OR), 95 % confidence intervals (95 % CI), and P values were calculated by applying logistic regression analysis. All data were analyzed using Statistical Package for Social Sciences (SPSS) software™ 20.0 (IBM Corp., Armonk, NY, USA).

Results {#Sec9}
=======

Patient characteristics {#Sec10}
-----------------------

Serum samples of 38 of the 105 patients who participated in the side study measuring fT4 and TSH concentrations at different time-points during chemotherapy treatment were of sufficient quality and quantity for analysis of fT4 and TSH. None of the patients had a thyroid disorder or were on thyroid replacement therapy at baseline, and further clinical characteristics of the 38 women are given in Table [1](#Tab1){ref-type="table"}. Patient characteristics are comparable with the characteristics of the whole cohort of the NEOZOTAC trial \[[@CR20]\].Table 1Patient characteristicsPatients (*N* = 38) NEOZOTACMedian Age (range), Years49 (34--65)WHO-status 034 (89.5 %) 12 (5.8 %) Unknown2 (5.8 %)T-classification cT222 (57.9 %) cT3 or cT416 (42.1 %)N-classification cN019 (50.0 %) cN+19 (50.0 %)Tumor type Ductal27 (71.1 %) Lobular7 (18.4 %) Other3 (7.9 %) Unknown1 (2.6 %)Hormone receptor status ER+ and/or PR+33 (86.8 %) ER− and PR−5 (13.2 %)Allocated treatment TAC20 (52.6 %) TAC+ZA18 (47.4 %)pCR Yes6 (15.8 %) No31 (81.6 %) Unknown1 (2.6 %)*ER* estrogen receptor, *PR* progesterone receptor, *ZA* zoledronic acid, *pCR* pathologic complete response

Thyroid function in breast cancer patients during chemotherapy {#Sec11}
--------------------------------------------------------------

Serum samples at baseline, before the 2nd chemotherapy cycle and at end of treatment were available for 31, 30, and 21 patients, respectively. Baseline fT4 and TSH levels were compared with values before the 2nd and 6th chemotherapy cycle. FT4 levels decreased, and TSH levels increased significantly during chemotherapy treatment. None of the patients had TH values under or above the reference value. Mean values of fT4 and TSH before cycle 1, 2, and 6 are shown in Fig. [1](#Fig1){ref-type="fig"}. The given *P* values are based on the tested values of the first and the last cycles. There were no significant differences between subjects solely treated with TAC chemotherapy and subjects treated with zoledronic acid as an adjunct to TAC with respect to the mean fT4 and TSH levels at each time point. Chemotherapy adjustments were made in four patients; one patient stopped after 4 cycles TAC, one patients after 5 cycles, and two patients received only less cycles of docetaxel (1 and 3 cycles less, respectively), because of toxicity. No dose reductions were done. No significant differences were seen in the decline of fT4 (*P* = 0.354) and increase of TSH (*P* = 0.770) between patients with chemotherapy adjustments compared with patients who received all six cycles of TAC.Fig. 1Serum fT4 and TSH levels baseline and during chemotherapy

Association between alterations of thyroid function and side effects during chemotherapy {#Sec12}
----------------------------------------------------------------------------------------

The relation between toxicity, per side effect of CTC grade II or more, and baseline values, as well as the variation in fT4 and TSH levels during chemotherapy was tested. There was no significant association between baseline fT4 and TSH and manifest side effects. However, a small decline of fT4 in the course of treatment, as reflected by a high ratio of fT4 levels at cycle 6 over fT4 levels at baseline, was associated with neuropathy, nausea, and vomiting grade II or more (Table [2](#Tab2){ref-type="table"}). The ratio of TSH levels between pre and post-chemotherapy was not associated with side effects.Table 2Ratio of fT4 levels at cycle 6 over fT4 levels at baseline in relation to experienced side effectsSide effect (grade II or more)*N*Ratio fT4 (%)OR^a^ (95 % CI)*P* valueRatio TSH (%)OR^a^ (95 % CI)*P* valueNeuropathyYes 1889 2.56 (1.00--6.56)**0.050**200 1.02 (0.97--1.07)0.517No 1281 163 VomitingYes 795 3.36 (1.04--10.87)**0.043**163 0.99 (0.93--1.05)0.664No 2384 191NauseaYes 2090 2.99 (1.07--8.37)**0.037**150 0.96 (0.91--1.01)0.094No 1080 255 AlopeciaYes 1391 2.45 (0.98--6.13)0.056171 0.99 (0.94--1.04)0.663No 1783 196 FatigueYes 2786 1.17 (0.38--3.61)0.780185 1.00 (0.93--1.08)0.996No 384 185 MucositisYes 1087 1.11 (0.56--2.22)0.759222 1.02 (0.98--1.07)0.352No 2086 166 DiarrheaYes 793 2.38(0.91--6.22)0.078107 0.92 (0.82--1.04)0.188No 2384 209 NeutropeniaYes 286 0.88 (0.23--3.38)0.939320 1.05 (0.97--1.13)0.640No 2885 175 AnemiaYes 392 1.58 (0.57--4.41)0.38299 0.91 (0.74--1.12)0.381No 2786 195 ThrombocytopeniaYes 185 0.88 (0.14--5.74)0.895548 1.21 (0.63--2.31)0.569No 2986 173 Overall grade III/IVYes 685 0.86 (0.37--2.00)0.730178 1.00 (0.94--1.06)0.903No 2487 187 Bold values indicate that *p*\<0.05, *OR* odds ratio, *CI* confidence interval^a^OR is given per 10 percent increase in ratio fT4 or TSH

The predictive value of thyroid function on efficacy of chemotherapy {#Sec13}
--------------------------------------------------------------------

FT4 and TSH levels were compared between subjects with and without pCR. PCR was achieved in 16 % of the patients (6/37 and 1 unknown), and the pCR rate varied in the different subtypes, which is comparable with the whole cohort of the NEOZOTAC trial \[[@CR20]\]. In hormone receptor-positive breast cancer, the pCR rate was 12.5 % (4/32), compared to 40 % (2/5) in the triple-negative patients.

FT4 and TSH levels were not related to pCR (Table [3](#Tab3){ref-type="table"}). High TSH levels were associated with pCR in univariate analysis, but this was not significant in multivariate analysis. Although axillary lymph node status, tumor size, and hormone receptor status were not significantly associated with pCR, these clinicopathological factors were included in the multivariate model, as they were associated with pCR in earlier research \[[@CR22], [@CR23]\]. The total dose of chemotherapy was also included in the multivariate model.Table 3Univariate and multivariate logistic regression models of pCR and TSH and fT4Univariate analysisMultivariate analysisOR95 % CI*P* valueOR95 % CI*P* valueClinical axillary lymph node: Pos versus Neg0.940.16--5.390.942Clinical tumor size: \>5cm versus \<5cm0.610.10--3.820.595ER+/PR+ receptor: Pos versus Neg0.210.27--1.700.154Total dose of CT1.010.88--1.160.915fT40.780.43--1.420.4170.660.33--1.290.223TSH3.241.09--9.70**0.035**19.70.77--5040.072Bold value indicates that *p*\<0.05, *pCR* pathological complete response, *ER* estrogen receptor, *PR* progesterone receptor, *OR* odds ratio, *CI* confidence interval in multivariate model adjusted for axillary lymph node status, tumor size and hormone receptor status

Discussion {#Sec14}
==========

This study shows that thyroid function declines during treatment in stage II/III HER2-negative breast cancer patients treated with neoadjuvant TAC chemotherapy. Interestingly, fT4 levels decreased less in patients with side effects of therapy compared to patients without side effects.

The decline of fT4 concentrations and increase of TSH concentrations during TAC observed in our study may reflect damage to the thyroid gland inflicted by the chemotherapy. In keeping with this inference, breast cancer survivors have a high cumulative incidence of overt primary hypothyroidism during long-term follow-up \[[@CR24]\], and therefore, it would be interesting to measure fT4 and TSH concentrations during follow-up to evaluate whether or not the concentrations normalize after neoadjuvant chemotherapy. Alternatively, the increase of TSH we observed could also be explained in the context of recovery of "non thyroidal illness" (NTI), an adaptive response to (chemotherapy-induced) cellular damage. In critically ill patients, the hypothalamus-pituitary-thyroid axis down-regulates as an adaptation to adverse physical conditions \[[@CR25]\]. Analogously, in another study of breast cancer patients treated with TEC or FEC, NTI-like plasma markers were observed one to 3 days after chemotherapy administration \[[@CR19]\], suggesting that NTI may be a primary adaptive response to chemotherapy-induced cellular damage. In apparent contrast to our data, NTI is marked by a decline of TSH and secondary hypothyroidism, unlike the increase of TSH observed in our study. However, during recovery of critical illness and NTI, TSH levels tend to be increased \[[@CR25]\]. Thus, the elevation of TSH we observed 3 weeks after chemotherapy administration, may in fact reflect the recovery of immediate adaptations of thyroid function (NTI) in response to treatment-induced cellular damage.

Whatever the cause of the chemotherapy-associated decline of fT4 we observed, a large reduction of fT4 concentrations in the course of 6 cycles TAC was associated with less (cumulative) side effects in terms of neuropathy, vomiting, and nausea of CTC grade II or higher. It is conceivable that lower levels of fT4 during chemotherapy, as an adaptive response, protect the body against tissue damage by down-regulating cellular metabolism. Interestingly, and potentially in analogy, low fT4 levels appear to protect people against the perils of old age, as low fT4 was associated with the longest lifespan in a population-based study of the elderly \[[@CR26]\].

Influence of thyroid function on efficacy of cancer therapies has been described \[[@CR27]\]. For example, in renal cancer patients treated with sunitinib, one-third of the patients experienced hypothyroidism as a side effect \[[@CR27], [@CR28]\], which had a positive impact on treatment outcome \[[@CR29], [@CR30]\]. Also, in a phase I/II study, propylthiouracil-induced chemical hypothyroidism was associated with a significantly longer median survival in glioma patients treated with high-dose tamoxifen \[[@CR6]\]. Moreover, in patients with head and neck cancer, hypothyroidism due to radiotherapy tended to be associated with improved survival retrospectively \[[@CR13]\]. However, we could not show that a low fT4 or a high TSH has a positive impact on chemotherapy efficacy.

It seems important to emphasize that the sample size of our study is small. Therefore, the results clearly need validation in a larger cohort which is planned in an ongoing trial in patients with early breast cancer (NCT02126449).

In conclusion, thyroid function declines during chemotherapy, and a large reduction of circulating fT4 is associated with less side effects of treatment. The results of our explorative study urge further evaluation of the impact of TH on cancer therapy.
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